Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181712 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cell Therapy for Lung Rejection
A Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT02181712: Completed Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject, sponsored by Mayo Clinic.
NCT02181712 is a Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02181712, a Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety and feasibility of mesenchymal stem cells therapy in patients with transplant related bronchiolitis obliteran syndrome (BOS)
Primary Outcome
Patients will be assessed for their capacity to tolerate IV infusion of MSC without acute clinical or physiological deterioration.
Conditions Studied
Interventions
- BIOLOGICAL Mesenchymal stem cell 0.5
- BIOLOGICAL Mesenchymal stem cell 1.0
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 1 |
What the finished NCT02181712 record still lists
NCT02181712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 2 interventions - of which Mesenchymal stem cell 0.5 is the first listed.
NCT02181712 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02181712 about?
NCT02181712 is a clinical study titled "Mesenchymal Stem Cell Therapy for Lung Rejection". To assess the safety and feasibility of mesenchymal stem cells therapy in patients with transplant related bronchiolitis obliteran syndrome (BOS)
What is the current status of trial NCT02181712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-07. Estimated completion is 2021-08-12.
What conditions does trial NCT02181712 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans, Lung Transplant Reject.
What interventions are being tested in trial NCT02181712?
The interventions under investigation include: Mesenchymal stem cell 0.5 (BIOLOGICAL), Mesenchymal stem cell 1.0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02181712?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02181712 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02181712's enrollment target sits among peer trials
19 8th of 9 higher than 2 of 9 other Bronchiolitis Obliterans trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiolitis Obliterans trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
-
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
RECRUITING
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
RECRUITING
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia